Article
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
The Lancet. Infectious diseases - 1 Jul 2013
Sulkowski Mark, Pol Stanislas, Mallolas Josep, Fainboim Hugo, Cooper Curtis, Slim Jihad, Rivero Antonio, Mak Carmen, Thompson Seth, Howe Anita Y M, Wenning Larissa, Sklar Peter, Wahl Janice, Greaves Wayne
Abstract excerpt
BACKGROUND: Rates of sustained virological response (SVR) to peginterferon-ribavirin are low in patients with hepatitis C virus (HCV) genotype 1 and HIV. We aimed to assess efficacy and safety of triple therapy with boceprevir plus pegylated interferon alfa-2b (peginterferon) and ribavirin, which increases rates of SVR in patients with HCV alone. METHODS: In our double-blind, randomised controlled phase 2 trial,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.